コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tumours, consistent with the inactivation of dihydropyrimidine dehydrogenase: a selective decrease in
2 Eniluracil (776C85), a potent inactivator of dihydropyrimidine dehydrogenase, allows fluorouracil (5-
3 ples include thiopurine S-methyltransferase, dihydropyrimidine dehydrogenase and flavin monooxygenase
6 bolite 5-methyl tetrahydrofolate (MTHF), and dihydropyrimidine dehydrogenase (DPD) activity in periph
10 cause of intolerance to fluoropyrimidines is dihydropyrimidine dehydrogenase (DPD) deficiency, which
14 ve reported a correlation between intratumor dihydropyrimidine dehydrogenase (DPD) messenger RNA (mRN
15 ected dose of 5-FU is rapidly inactivated by dihydropyrimidine dehydrogenase (DPD) to therapeutically
16 ficiency of the pyrimidine catabolic enzyme, dihydropyrimidine dehydrogenase (DPD), has been shown to
17 e uracil in UFT slows degradation of 5-FU by dihydropyrimidine dehydrogenase (DPD), which results in
19 in the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie, DPYD*2A) is st
20 ral regimen of eniluracil (which inactivates dihydropyrimidine dehydrogenase [DPD]), 5-FU, and leucov
21 enzyme in the pyrimidine catabolic pathway, dihydropyrimidine dehydrogenase (DPYD) and its effect on
22 n addition, AEG-1 enhances the expression of dihydropyrimidine dehydrogenase (DPYD) that catalyzes th
24 red study with eniluracil, an inactivator of dihydropyrimidine dehydrogenase, enabling catabolite cor
27 acy; in the XELOX group, for high versus low dihydropyrimidine dehydrogenase expression levels, DFS H
28 shown the prognostic impact of several rare dihydropyrimidine dehydrogenase gene (DPYD) variants on
30 e to progression (TTP) of an oral regimen of dihydropyrimidine dehydrogenase inhibitory fluoropyrimid
32 pidermal growth factor receptor mutation, or dihydropyrimidine dehydrogenase polymorphism) may differ
33 and other drug metabolizing enzymes such as dihydropyrimidine dehydrogenase represents a major innov
34 acil (776C85) is an effective inactivator of dihydropyrimidine dehydrogenase that allows continuous l
35 acil is being developed as an inactivator of dihydropyrimidine dehydrogenase, the enzyme that brings
36 routine use of p53, ras, thymidine synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。